AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
I-Mab Soars 11.15% on Promising Givastomig Trial Data
Generated by AI AgentAinvest Pre-Market Radar
Thursday, Jun 26, 2025 9:03 am ET1min read
On June 26, 2025, I-Mab's stock surged by 11.15% in pre-market trading, reflecting significant investor optimism and market confidence in the company's recent developments.
I-Mab's stock price has been positively influenced by the release of encouraging data from its Phase 1b clinical trial for Givastomig. The trial demonstrated a 71% objective response rate (ORR) per RECIST v1.1, with a favorable safety profile. Notably, an 83% ORR was observed in patients across selected doses, indicating strong efficacy in the treatment of gastric cancers.
Additionally, I-Mab's presentation at the ESMO Gastrointestinal Cancers Congress 2025 further bolstered investor confidence. The company highlighted positive data from the Phase 1b study, which included a combination of Givastomig with immunochemotherapy in patients with first-line gastric cancers. This data underscores the potential of Givastomig as a promising therapeutic option, driving investor enthusiasm and contributing to the stock's upward trajectory.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Serve Robotics Surges 5.16% as Trump Admin Boosts Robotics Push, Eyes 10X Revenue by 2026
Dec.12 2025
New Pacific Metals (NPM) Soars 7.98% as Base Metals Market Anticipates Supply/Demand Shifts
Dec.12 2025
Gevo Inc. (GEVO) Surges 6.22% on $26M BioRecro Partnership to Expand Carbon Management Capabilities
Dec.12 2025
Sable Offshore Soars 5.82% as Private Placement and Policy Tailwinds Drive Pre-Market Rally
Dec.12 2025
Mastercard Inc. Surges 4.55% as Fintech Optimism and AI Expansion Drive Pre-Market Rally
Dec.12 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet